Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21 abstract 272
we had the pleasure during the virtual 2021 g you cancer symposium to present the first in kind trial combining his two inhibitor, uh, LGT fan with the the Kabul with Cables Internet, which is a multi tyrosine kinase inhibitor of federal receptor as well as meant excel. And this was part of a two covert study untreated patient cohort one and previously treated patient cohort to And we are presenting during the G o Cancer symposium Cohort to that finished a cruel and we enrolled patients that were previously treated 1 to 2 prior line of therapy. And despite that, there were some those reduction the combination overall side effects were manageable in a way. And, uh, less than 20% of patients discontinued any drug due to a treatment emergent adverse event. So in a nutshell, the combination shows a preliminary promising activity. The side effects were manageable. Most of the treatment related side effects were great. One and two, we didn't have any great four and five and I think a strategy by targeting the transcription factor. The master regulator here, um, in renal and clear cell RCC have to envy Jeff inhibition through caboose, Anthony, maybe really an effective treatment for patients with metastatic renal cell. And we look forward in the to update our results later on, with more follow up, especially to report on cohort one, which is a which is the same combination in untreated, metastatic, clear cell RCC patients. Thank you.
